Abstract Human immunodeficiency virus type 1 (HIV-1) Tat plays an important role in HIV-associated neuropathogenesis; the underlying mechanisms are still evolving. We have recently shown that HIV-1 Tat induces expression of glial fibrillary acidic protein (GFAP), a characteristic of HIV-1 infection of the central nervous system. We have also shown that the Tat-induced GFAP expression in astrocytes is regulated by p300 and that deletion of the early growth response 1 (Egr-1) cis-transacting element within the p300 promoter abolishes Tat-induced GFAP expression. In this study, we further examined the relationship between Tat and Egr-1 in astrocytes. We found increased Egr-1 protein expression in Tat-expressing human astrocytoma cells and mouse primary astrocytes. Using the Egr-1 promoter-driven firefly luciferase reporter gene assay and the site-directed mutagenesis, we demonstrated that Tat increased Egr-1 expression by transactivating the Egr-1 promoter and involving specific serum response elements within the promoter. Consistent with these data, we showed that Tat transactivation of the Egr-1 promoter was abrogated when astrocytes were cultured in serum-reduced media. Taken together, these results reveal that Tat directly transactivates Egr-1 expression and suggest that Tat interaction with Egr-1 is probably one of the very upstream molecular events that initiate Tat-induced astrocyte dysfunction and subsequent Tat neurotoxicity.
Introduction
Infection of the central nervous system (CNS) by HIV-1 often causes neurological disorders such as dementia in AIDS patients (Price et al. 1988 ). The main neuropathologies are astrocytosis and cerebral atrophy in the early stage of infection and formation of myelin pallor, multinucleated giant cells, neuron degeneration, and an abnormal bloodbrain barrier in the later stage of the disease (Bell et al. 2006; Brew 2009; Cohen and Gongvatana 2009; Del Valle and Pina-Oviedo 2006; Ellis et al. 2007; Sacktor 2002) . In the era of highly active anti-retroviral therapy, a mild form of neurological disorder called mild cognitive and motor disorder has become more prevalent among HIV-infected subjects (Brew 2009; Cohen and Gongvatana 2009; Sacktor 2002) . In the brain, the primary cell targets for HIV infection are macrophages/microglia and, to a lesser extent, astrocytes (Gorry et al. 1998; Lee et al. 1993; Liu et al. 2004; Saito et al. 1994; Schweighardt and Atwood 2001; Tornatore et al. 1994 ). However, neurons that are mostly affected in the brain of HIV-infected individuals are rarely infected. Therefore, a number of indirect mechanisms have been proposed for HIV-associated neuropathogenesis. In general, these indirect mechanisms can be grouped into three main categories: improper immune activation, soluble factors of both viral and host origins, and astrocyte dysfunction.
Among the soluble factors is the HIV-1 Tat protein. Tat is present in the serum and the brain of HIV-infected individuals (Bratanich et al. 1998; Cupp et al. 1993; Kolson et al. 1993; Parmentier et al. 1992; Westendorp et al. 1995a; Xiao et al. 2000) . It causes direct neurotoxicity by various mechanisms including neuroexcitation, Ca 2+ flux, and oxidative stress (Chen et al. 1997; Cheng et al. 1998; Conant et al. 1998; Hofman et al. 1993 Hofman et al. , 1994 Hofman et al. , 1999 Jones et al. 1998; Liu et al. 2000; Sabatier et al. 1991; Westendorp et al. 1995b; Zidovetzki et al. 1998; Zocchi et al. 1998) . It can also affect neuronal proliferation and differentiation through interaction with cell cycle-related proteins (Milani et al. 1993; . Moreover, Tat could also specifically affect neuronal functions through its uptake, followed by altering neuronal gene expression (Bonifaci et al. 1995; Frankel and Pabo 1988; Green et al. 1989; Liu et al. 2000; Mann and Frankel 1991; Viscidi et al. 1989; Westendorp et al. 1995a; Xiao et al. 2000) . Furthermore, Tat itself possesses the chemoattractant activity and induces excessive CNS infiltration of neutrophils, macrophages, and monocytes, which in turn affect neuron survival and function (Chen et al. 1997; Cheng et al. 1998; Conant et al. 1998; Jones et al. 1998; Kim et al. 2003; Liu et al. 2000) .
More evidence has begun to emerge to indicate that Tat interaction with astrocytes also contributes to Tat neurotoxicity. Tat alters astrocytes and neurons to form aggregates and the neuritic processes to coalesce into fascicles in cultures (Kolson et al. 1993) . Tat induces MCP-1 expression in and release from astrocytes, and MCP-1 level in the cerebrospinal fluid correlates with AIDS dementia (Conant et al. 1998) . In addition to MCP-1, Tat also induces the expression of several other cytokines and chemokines, including IL-1β, IL-6, Rantes, and CXCL10 (El-Hage et al. 2005; Nath et al. 1999; Williams et al. 2009) . We have recently shown that Tat enhances GFAP expression in astrocytes and impairs astrocyte function and that GFAP dysregulation is directly involved in Tat neurotoxicity Zhou et al. , 2007 . Furthermore, we have shown that the transcriptional co-activator p300 regulates Tat-induced GFAP up-regulation through transcription factor early growth response 1 (Egr-1) (Zou et al. 2009, in preparation) . In this study, we aimed to analyze the relationship between Tat and Egr-1 in astrocytes and the possible roles of Egr-1 in the regulation of Tat interaction with astrocytes and Tat neurotoxicity.
Materials and methods

Cells and cell cultures
293T cells, U373.MG and U87.MG, were purchased from American Tissue Culture Collection (ATCC, Manassas, VA). These cells were maintained in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal bovine serum (FBS), 50 U/ml penicillin, and 50 μg/ml streptomycin in a 37°C, 5% CO 2 incubator. Primary astrocytes were isolated from 18.5-day-old embryonic brain tissue of the Tat-inducible transgenic mice described previously . Briefly, the cortex of the mouse embryonic brain tissue was aseptically and mechanically separated and dissociated in Ca 2+ /Mg 2+ free Hanks balanced salt solution (HBSS) with 0.035% sodium bicarbonate and 1 mM sodium pyruvate (pH 7.4) and then treated with 0.25% trypsin at 37°C for 30 min. Trypsin digestion was halted by washing cells with Ca 2+ /Mg 2+ free HBSS supplemented with 10% FBS, followed by lowspeed centrifugation to remove debris. Cells were suspended and plated at an appropriate density in F12-K medium (Cellgro, Manassas, VA) containing 10% FBS, 50 U/ml penicillin, and 50 μg/ml streptomycin. Culture medium was changed 24 h following the initial plating and then every 3-4 days in order to remove non-adherent cells; primary astrocytes were used after three to four passages. Plasmids pcDNA3, pGL3-basic, and pCMV-βgal were purchased from Clonetech (Mountain View, CA). pcTat.Myc was previously described . For pEgr-1p-Luc, the full-length human Egr-1 promoter (about 700 bp) was amplified from the genomic DNA of U87 cells and cloned into pGL3-basic using MluI and XhoI to produce pEgr-1p-Luc. pEgr-1p-Luc was then digested with ScaI to remove 468 bp at the 5′ end of the Egr-1 promoter; the resulting DNA was ligated to generate the plasmid pEgr1pΔ468-Luc. Similarly, pEgr-1pΔ260-Luc was made using MluI/PvuII. pEgr-1pΔEBS-Luc was constructed using a QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) and pEgr-1p-Luc as the template and primers 5′-GCG ATA GAA CCG CGG CCC GAC TCG CCG CGG GTC TGG GCT TCC CCA GCC T-3′ and 5′-AGG CTG GGG AAG CCC AGA CCC GCG GCG AGT CGG GCC GCG GTT CTA TCG C-3′ (SacII sites in bold). pEgr-1pΔEBSΔTRE was obtained by digesting pEgr-1pΔEBS-Luc with SacII, followed by ligation. All recombinant plasmids were verified by sequencing.
Transfections and Western blot analysis U373.MG were plated in a 12-well plate at a density of 2× 10 5 /well or a six-well plate at a density of 4×10 5 /well and transfected with plasmids using the standard calcium phosphate precipitation methods. Cells were harvested 24 h after transfection for RNA analysis and 72 h after transfection for protein analysis and reporter gene assays. Cells were washed once in ice-cold phosphate-buffered saline (PBS) and lysed in a RIPA buffer [50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 2 mM PMSF, and 1X protease inhibitor cocktail (Roche, Indianapolis, IN)] on ice for 20 min to obtain whole cell lysates. For GFAP, cells were lysed in a Triton buffer [20 mM Tris-HCl, pH 7.5, 5 mM EDTA, 150 mM NaCl, 1% Triton X-100, 1X protease inhibitor cocktail (Roche)] on ice for 20 min. The pellets were then extracted with 4× SDS polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer (0.2 M TrisHCl, pH 6.8, 8% SDS, 50 mM EDTA, 40% glycerol, 0.08% bromophenol blue, and 4% β-mercaptethanol) and heated at 60°C for 30 min, then at 100°C for 10 min, and then used to determine for GFAP expression. Protein concentration was determined using a Bio-Rad DC protein assay kit (Bio-Rad, Hercules, CA). Cell lysates were subjected to 10% SDS-PAGE and Western blot analysis with appropriate primary antibodies, HRP-labeled secondary antibodies, and an ECL chemiluminescence kit (Amersham, Piscataway, NJ). α-GFAP and α-actin antibodies were from Sigma (St. Louis, MO), and α-Egr-1 and α-Myc antibodies were from Santa Cruz Biotechnologies (Santa Cruz, CA).
RNA isolation and semiquantitative RT-PCR
Total RNA was isolated using a Trizol Reagent kit (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Reverse transcription PCR (RT-PCR) was performed on a PE Thermocycler 9700 (PE Applied Biosystem, Foster City, CA) using a Titan One Tube RT-PCR kit (Boehringer Mannheim, Indianapolis, IN) with Tat primers 5′-GTC GGG ATC CTA ATG GAG CCA GTA GAT CCT-3′ and 5′-TGC TTT GAT AGA GAA ACT TGA TGA GTC-3′, GFAP primers 5′-AAG CAG ATG AAG CCA CCC TG-3′ and 5′-GTC TGC ACG GGA ATG GTG AT-3′, and GAPDH primers 5′-CTC AGT GTA GCC CAG GAT GC-3′ and 5′-ACC ACC ATG GAG AAG GCT GG-3′. All the reactions were performed with the program of 50°C for 30 min, 94°C for 2 min, followed by ten cycles of 94°C for 15 s, 55°C for 1 min, and 72°C for 1 min and 25 cycles of 94°C for 15 s, 58°C for 1 min and 72°C for 1 min, then one cycle of 72°C for 7 min. The expected sizes for GFAP, Tat, and GAPDH amplification products were 625, 216, and 500 bp, respectively. Control RT-PCR reactions containing no reverse transcriptase were included to ensure no genomic DNA contamination.
Preparation of pseudotyped HIV-GFP virus and infection of U373.MG cells
293T cells were transfected with pHIV-GFP plasmid and pHCMV-G plasmid using the standard calcium phosphate precipitation method. The culture supernatant was collected 48 h after the medium change, briefly centrifuged to remove cell debris, and used as the virus stock. U373.MG cells were infected with vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped HIV-GFP viruses in the presence of 8 μg/ml polybrene at 37°C for 2 h. The cells were then thoroughly washed with culture medium to remove unbound viruses and cultured for additional 48 h. The dosages of the viruses for infection were titrated for U373.MG to ensure minimal cell death and maximal infection efficiency.
Reporter gene assays
Cells were harvested in ice-cold PBS and collected by brief centrifugation. Cell lysates were obtained for the firefly luciferase assay according to the manufacturer's instruction (Promega, Madison, WI). The luciferase activity was quantitated using an Opticomp Luminometer (MGM Instruments, Hamden, CT). For β-galactosidase reporter gene assay, 30 μl cell extract was mixed with 3 μl 100× Mg 2+ solution (0.1 M MgCl 2 and 4.5 M β-mecaptoethanol, 66 μl 4 mg/ml O-nitrophenyl-β-D-galactopyranoside in 0.1 M sodium phosphate, pH 7.5, and 201 μl 0.1 M sodium phosphate, pH 7.5). The mixture was incubated at 37°C for 30 min, and the optical density at 405 nm was determined and expressed as the relative β-galactosidase activity. β-galactosidase activity was then used to normalize the transfection variations for the luciferase reporter gene assay.
Data analysis
All experiment data were analyzed by two-tailed Student's t test. A p<0.05 was considered to be statistically significant and labeled "*"; a p<0.01 was considered to be statistically highly significant and labeled "**".
Results
Egr-1 up-regulation in Tat-expressing U373.MG, U87.MG, and primary astrocytes Our previous studies suggest that Egr-1 is likely directly involved in Tat-induced p300 and GFAP expression in astrocytes. Egr-1 gene belongs to a group of early response genes and regulates the expression of a wide spectrum of cellular genes; it functions as a convergence point for many intracellular signaling cascades. Thus, we examined the relationship between Tat expression and Egr-1 expression. We first transfected Tat-expressing plasmid into human astrocytoma cells U373.MG and determined Egr-1 expression by Western blot analysis. The results showed that Tat expression in these cells was accompanied by increased Egr-1 protein expression (Fig. 1a) . Similar results were obtained in another widely used human astrocytoma cells U87.MG (Fig. 1b) . To further examine the phenomenon, we isolated primary astrocytes from the brain of inducible and astrocyte-specific Tat transgenic mice (Kim et al. 2003; Zou et al. 2007 ). We then cultured these cells with doxycycline (Dox) for 0, 1, 2, and 3 days. We also included primary astrocytes from wild-type C57/BL6 mice in which the Tat transgenic mice were bred as a control in these experiments. As shown previously, Tat expression was induced in these primary cells by Dox over time, as demonstrated by RT-PCR (Fig. 1c, top panel) . In parallel, there was induction of Egr-1 protein expression in these cells (Fig. 1c, middle panel, shown by asterisk) . In contrast, Egr-1 expression showed no changes in Dox-treated wildtype primary astrocytes (Fig. 1d) . We next determined whether HIV-1 infection would also lead to increased Egr-1 expression in astrocytes. To facilitate HIV entry into these cells, we took advantage of the VSV-G pseudotyped replication-defective HIV-GFP reporter virus. U373.MG cells were infected with this virus at different multiplicities of infection (MOI) as indicated. Cells were then harvested for Western blot analysis. The results showed that Egr-1 expression was gradually induced at a MOI lower than 1 and maximized at MOI of 1 and then decreased to the basal level when the MOI exceeded 1 (Fig. 1e) . GFAP expression showed a similar expression kinetics in HIV-infected astrocytes, which further support our previous finding that Egr-1 regulates GFAP expression (Zou et al., in preparation) . HIV infection was verified by p24 and GFP expression in these cells. Taken together, these results indicate that Egr-1 is induced in astrocytes either by Tatexpressing alone or by HIV-1 infection.
Up-regulation of the Egr-1 promoter activity in astrocytes by Tat Next, we wished to determine whether Tat enhanced Egr-1 expression at the transcriptional level. To address this possibility, we created a firefly luciferase (Luc) reporter gene under the control of the human Egr-1 promoter pEgr1p-Luc. U373.MG cells were transfected with pEgr-1p-Luc and different amounts of Tat-expressing plasmid as indicated. pCMV-βgal was included in the transfection as a transfection efficiency control for normalization, while pcDNA3 was added to equalize the total amount of DNA among the transfections. The cells were harvested for cell Fig. 1 Egr-1 up-regulation in Tat-expressing U373 cells, U87 cells, and primary astrocytes. Cells were transiently transfected with pCDNA3 or pcTat.Myc and harvested after 72 h. Cell lysates of U373 (a) and U87 (b) cells were analyzed for Tat and Egr-1 expression, with β-actin included as a loading control. Primary astrocytes were prepared from brain-targeted inducible Tat transgenic mice and cultured in the absence or presence of 5 μg/ml doxcycline (Dox) for up to 3 days (c) then analyzed for Tat and Egr-1 expression. Total RNA was isolated and subjected to RT-PCR using Tat-specific primers with GAPDH used as a loading control. As a control, primary astrocytes were also prepared from wild-type C57/BL6 mice, treated with Dox, and analyzed for Egr-1 expression (d). Meanwhile, U373 cells were infected with increasing amounts of VSV-G pseudotyped HIV-GFP virus and harvested after 72 h. Cell lysates were analyzed for Egr-1, GFAP, and Tat expression (e), along with p24 and GFP to ensure infection efficiency. β-actin was included as a loading control. Data are representative of at least three independent experiments lysates for the reporter gene assays as well as protein expression analysis. The results showed that Tat increased the Egr-1 promoter-driven Luc reporter gene expression when the input amount of Tat was below 0.2 μg (Fig. 2, top panel) . Further increase of the input amount of Tat led to decreases in the Luc reporter gene expression, which is likely due to the anti-proliferative effects of Tat on these cells . In agreement with the reporter gene data, Egr-1 protein expression exhibited a similar kinetics (Fig. 2, bottom  panel) . In addition, GFAP protein expression was in parallel with that of Egr-1. These results suggest that Tat-induced Egr-1 expression likely results from transactivation of the Egr-1 promoter transcription.
Analysis of the functional elements of the human Egr-1 promoter in response to Tat expression To further examine the mechanism of Tat-induced Egr-1 up-regulation, we investigated the importance of the cisacting elements of the Egr-1 promoter. There are several putative DNA binding sites for transcription factors including one Sp1 site, two cAMP response elements, one 12-O-tetradecanoyl phorbol 13-acetate response element (TRE), one Egr-1 binding site (EBS), and five serum response elements (SRE) within the human Egr-1 promoter (Aicher et al. 1999; Schwachtgen et al. 2000) . Thus, we first constructed a deletion mutant Δ468 that was deleted the 468-bp fragment of the Egr-1 promoter at the 5′ end (Fig. 3, left panel) and determined its effects on Tat-induced Egr-1 transactivation. We then performed similar transfections as above with the reporter plasmid and 0.2 μg Tat plasmid. Compared to the full-length Egr-1 promoterdriven reporter (FL), Δ468 showed a significantly lower Fig. 2 Egr-1 promoter activity and expression of Egr-1 protein increases in the presence of a specific amount of Tat. U373 cells were transiently transfected with Egr-1 promoter-driven luciferase reporter plasmid pEgr-1p-Luc or control plasmid pGL3 along with increasing amounts of pcTat.Myc and harvested 72 h post-transfection. Half of the cells were to detect Egr-1 promoter activity (a) with pCMV-βgal used to normalize for variations in transfection efficiency. The remaining transfected cells were separated and used for Tritonsoluble (TS) and Triton-insoluble (TIS) fractions and analyzed for Egr-1, GFAP, and Tat expression, with β-actin included as a loading control (b) Fig. 3 Analysis of the functional elements of the human Egr-1 promoter in response to Tat expression. The full-length human Egr-1 promoter was cloned from the genomic DNA of U87 cells and inserted into pGL3 and then used to create a panel of Egr-1 promoter mutations (a). Cells were transiently transfected each pEgr-1p-luc mutant plasmid and either pcTat.Myc or pcDNA3, then harvested 72 h post-transfection. Cell lysates were used to determine luciferase activity (b), with pCMV-βgal included to normalize the transfection efficiency. Data are representative of at least three independent experiments Luc activity (Fig. 3, right panel) . Meanwhile, this deletion gave rise to no significant difference in the Luc activity between Tat and the cDNA3 control. In addition, we also constructed Δ260, ΔEBS, and ΔEBSΔTRE, which were deleted the 260-bp fragment at the 5′ end, the EBS binding site, and both EBS and TRE DNA binding sites, respectively, and determined their effects on Tat-induced transactivation of the Egr-1 promoter. Interestingly, compared to the full-length promoter, all deletion mutants showed a significant increase in the Luc activity, and the biggest increase was detected in ΔEBS-transfected cells. On the other hand, none of the mutants had significant changes in the Luc activity in Tatexpressing cells. Taken together, these results indicate that SRE1/2/3 are likely involved in Tat-induced Egr-1 transactivation. Moreover, these results also suggest that the Egr-1 promoter contains positive cis-elements SRE1/2/3 and negative cis-elements TRE and EBS for its transcriptional control.
Tat-induced Egr-1 up-regulation is modulated by SRE within the Egr-1 promoter
The SRE is the binding site for serum response factor, a ubiquitous 67-kDa protein whose binding is essential for the response of the promoter to serum stimulation (Treisman 1992) . Thus, to ascertain the role of SRE in Tat-induced Egr-1 expression, we determined Tat effects on the Egr-1 promoter-driven reporter gene activity in the serum-starved cells. We transfected U373.MG cells with the full-length Egr-1 promoter-driven Luc reporter with or without Tatexpressing plasmid and cultured these cells first for 24 h in the regular 10% FBS-containing medium and then in the medium containing no FBS for 24 h. Compared with the cells that were cultured in the regular 10% FBS-containing medium, serum starvation not only significantly decreased the basal activity of the Egr-1 promoter but also Tat-induced transactivation of the Egr-1 promoter (Fig. 4) . In contrast, serum starvation exhibited little effects on the activity of the Δ468 Egr-1 promoter. The slightly higher activity of the fulllength Egr-1 promoter and the slightly lower activity of the Δ468 Egr-1 promoter in the serum-starved cells than the activity of the Δ468 Egr-1 promoter in the 10% FBScultured cells are likely due to the presence of the other two SRE at the 3′ end of the Egr-1 promoter. These results provide further evidence to support that the SRE play important role in regulating Egr-1 transcription but also Tat-induced Egr-1 transactivation.
Discussion
In this study, we showed that Egr-1 protein level was upregulated in Tat-expressing human astrocytoma cell lines and mouse primary astrocytes and HIV-infected astrocytes. We then showed that Tat-induced Egr-1 up-regulation occurred at the transcriptional level. Moreover, we showed that SRE within the Egr-1 promoter were important for Tatinduced Egr-1 up-regulation.
HIV-1 Tat regulates the expression of a plethora of cellular genes, including several genes in astrocytes, as discussed above. In this study, we identified Egr-1 as a Tat- Fig. 4 Tat-induced Egr-1 up-regulation is modulated by the serum response element during starvation. U373 cells were transfected with either pEgr-1p-Luc (FL) or pEgr-1pΔ468-Luc (Δ468) along with pcTat.Myc or pcDNA3. At 16 h post-transfection, the media was replaced with DMEM containing reduced concentrations of serum and incubated for additional 48 h. Cell lysates were then used to determine luciferase activity, with pCMV-βgal included to normalize the transfection efficiency. Data are representative of at least three independent experiments Fig. 5 Egr-1 transcriptional network altered by HIV-1 Tat in astrocytes. HIV-1 Tat protein in astrocytes can be derived from direct HIV infection of these cells themselves. It can also be from HIVinfected microglia/macrophages, followed by its uptake by astrocytes. Tat then transactivates Egr-1 expression, which in turn transactivates p300 expression, which in turn transactivates GFAP expression. Activation of GFAP expression or expression of other target genes of Egr-1 and p300 leads to changes in astrocyte proliferation, survival, and function and, as a result, impairs neuronal integrity and survival positive regulatory target gene in astrocytes which functioned upstream of two other Tat-positive regulatory genes p300 and GFAP in these cells. Egr-1 is induced in HIVinfected monocytic and human CD4 + T lymphocytes (Dron et al. 1999) and astrocytes that were infected with HIV as shown in this study and other viruses (Cai et al. 2006; Romagnoli et al. 2008) . In contrast, two early studies have shown that HIV-1 Tat blocks nerve growth factor-induced Egr-1 expression in neurons (Darbinian et al. 2008; Darbinian-Sarkissian et al. 2006) . The discrete effects of Tat on Egr-1 expression are likely due to the differences between the target cells, i.e., among neurons, lymphocytes, and astrocytes. Nevertheless, the current study adds the Egr-1/p300/GFAP to the increasing number of the Tat target genes and supports the notion that altered cellular gene expression is an important indirect mechanism by which Tat contributes to HIV-associated neuropathologies in the brain.
HIV-1 Tat effects on host gene expression are thought to be mediated through indirect mechanisms since it has no DNAbinding activity. Our studies showed that Tat activated Egr-1 expression at the transcriptional level. The Egr-1 promoter has a number of cis-regulatory elements including the major SRE regulatory sequences, the SRE 1/2/3 (Aicher et al. 1999; Herbison et al. 1999) . In agreement with these findings, we showed that SRE 1/2/3 were the major regulator for Egr-1 expression as well as Tat-induced Egr-1 up-regulation. The SRE activity is highly responsive to a wide range of physiological stimuli and signals, mostly through various intracellular signaling pathways (Eugenin et al. 2007; Gineitis and Treisman 2001; Khachigian and Collins 1997; Peruzzi 2006 ). On the other hand, both intracellular and extracellular Tat has been linked to intracellular signaling pathways to regulate cellular gene expression and subsequently cell proliferation and survival (Eugenin et al. 2007; Gineitis and Treisman 2001; Khachigian and Collins 1997; Peruzzi 2006) . Thus, it is likely that Tat-induced Egr-1 upregulation results from cross talks with Tat-elicited intracellular signaling. Nevertheless, the exact mechanisms underlying the Tat-induced Egr-1 expression remain to be elucidated.
Egr-1, like other members of the immediate early gene family, functions as a convergence "gateway" for many signaling cascades and controls many biological functions by altering its target gene expression to couple extracellular signals to long-term responses. A growing list of genes has been identified to be Egr-1 regulatory targets. These include transcription factors such as Egr-1, cytokines such as TGF-β and IL-1, chemokines such as MIP-2, MCP-1, and neuronal genes (James et al. 2004; Petersohn et al. 1995; Treisman 1992) . Many of these genes clearly play key roles in cell proliferation and differentiation, pathological settings, and neuronal responses such as neuronal plasticity.
Interestingly, several recent studies have directly linked Egr-1 to astrocyte proliferation, glial scar formation, astrocyte function and neurite outgrowth, and survival of neuronal cells (Beck et al. 2008; Mayer et al. 2009; Mittelbronn et al. 2009; Shin et al. 2009 ). Thus, based on our previous studies and the current study, we propose an Egr-1-mediated astrocyte transcriptional cascade for Tat neurotoxicity (Fig. 5) . It begins with Egr-1 transactivation by Tat, produced by direction HIV infection of astrocytes, or secreted by HIV-infected macrophages/microglia and taken up by astrocytes or direct HIV infection of astrocytes. Egr-1 activation leads to p300 expression, which in turn activates GFAP expression in astrocytes or astrocytosis. Elucidation of the molecular pathways by which Tat activates Egr-1 expression presents a new opportunity to further discern the neuroprotective from the neurotoxic functions of astrocytosis and might lead to new approaches to modulate the time span and severity of astrocytosis, thus fine-tuning neuronal tissue repair and regeneration in the context of HIV infection.
